Development of a travelers' diarrhea vaccine for the military: how much is an ounce of prevention really worth?
Infectious diarrhea is one of the many threats to the deployed military, and given limited resources, a decision to pursue a vaccine acquisition strategy should be based on best evidence that weighs costs and benefits compared to alternatives. An economic model was developed to estimate the marginal cost to avert a duty day lost due to diarrhea for a vaccine acquisition strategy compared to current clinical management, for both multiplex and pathogen-specific vaccines. Vaccines against Campylobacter and enterotoxigenic Escherichia coli appeared to be more favorable than a Shigella vaccine. This model provides an evidence-based decision tool to support prioritization in vaccine development.
Riddle
Mark S
MS
Uniformed Services University of the Health Sciences, Bethesda, MD, USA. markriddlemd@hotmail.com
Tribble
David R
DR
Cachafiero
Santiago Pérez
SP
Putnam
Shannon D
SD
Hooper
Tomoko I
TI
D001428:Bacterial Vaccines / Q000191:economics* / Q000276:immunology*; D017281:Cost of Illness; D003967:Diarrhea / Q000191:economics* / Q000517:prevention & control*; D004756:Enterobacteriaceae Infections / Q000191:economics* / Q000517:prevention & control*; D022361:Escherichia coli Vaccines / Q000191:economics / Q000276:immunology; D006801:Humans; D008889:Military Personnel; D022281:Shigella Vaccines / Q000191:economics / Q000276:immunology
D001428:Bacterial Vaccines; D022361:Escherichia coli Vaccines; D022281:Shigella Vaccines